Molecular modeling of G-protein coupled receptor kinase 2: Docking and biochemical evaluation of inhibitors

AAPS PharmSci

Volumn 2, Issue 1, 2000, Pages 9-21

  Kassack, Matthias U ^a,e   Högger, Petra ^b   Gschwend, Daniel A ^c   Kameyama, Kimihiko ^d   Haga, Tatsuya ^d   Graul, Richard C ^a   Sadée, Wolfgang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Homology Modeling; Suramin; Suramin Analogues; Trifluoperazine

Indexed keywords

BETA ADRENERGIC RECEPTOR KINASE; BETA-ADRENERGIC RECEPTOR KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASES; DRUG DERIVATIVE; ENZYME INHIBITOR; GTP BINDING PROTEINS; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOQUINOLINE DERIVATIVE; N (2 (METHYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(METHYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; RHODOPSIN; SURAMIN; TRIFLUOPERAZINE;

ANIMAL; ARTICLE; BINDING SITE; CATTLE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; FACTUAL DATABASE; HUMAN; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; PROTEIN BINDING; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMAL; BINDING SITES; CATTLE; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DATABASES, FACTUAL; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HUMAN; IN VITRO; ISOQUINOLINES; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; RHODOPSIN; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURAMIN; TRIFLUOPERAZINE;

EID: 18044401022     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps020102     Document Type: Article

References (41)

1. Lefkowitz RJ. G protein-coupled receptor kinases. Cell. 1993;74:409-412.
2. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: Desensitization of beta-adrenergic receptor function [published erratum appears in FASEB J 1990 Sep; 4(12):3049].FASEB J. 1990;4:2881-2889.
3. Palczewski K, Benovic JL. G-protein-coupled receptor kinases. Trends Biochem Sci. 1991;16:387-391.
4. Haga T, Haga K, Kameyama K. G protein-coupled receptor kinases.J Neurochem. 1994;63:400-412.
5. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases.Annu Rev Biochem. 1998;67:653-692.
6. Benovic JL, DeBlasi A, Stone WC, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: Primary structure delineates a multigene family. Science. 1989;246:235-240.
7. Benovic JL, Regan JW, Matsui H, et al. Agonist-dependent phosphorylation of the alpha 2-adrenergic receptor by the beta-adrenergic receptor kinase. J Biol Chem. 1987;262:17251-17253.
8. Kwatra MM, Benovic JL, Caron MG, Lefkowitz RJ, Hosey MM. Phosphorylation of chick heart muscarinic cholinergic receptors by the beta-adrenergic receptor kinase. Biochemistry. 1989;28:4543-4547.
9. Haga K, Kameyama K, Haga T, Kikkawa U, Shiozaki K, Uchiyama H. Phosphorylation of human ml muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 and protein kinase C. J Biol Chem. 1996;271:2776-2782.
10. Pei G, Kieffer BL, Lefkowitz RJ, Freedman NJ. Agonist-dependent Phosphorylation of the mouse delta-opioid receptor: Involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol. 1995;48:173-177.
11. Benovic JL, Mayor FJ, Somers RL, Caron MG, Lefkowitz RJ. Light-dependent phosphorylation of rhodopsin by beta-adrenergic receptor kinase. Nature. 1986;321:869-872.
12. Benovic JL. Purification and characterization of beta-adrenergic receptor kinase. Methods Enzymol. 1991;200:351-362.
13. Knighton DR, Zheng JH, Ten Eyck LF, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase [see comments]. Science. 1991;253:407-414.
14. Zheng J, Knighton DR, Ten Eyck LF, Karlsson R, Xuong N, Taylor SS, Sowadski JM. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry. 1993;32:2154-2161.
15. Iino M, Shibano T. Substrate recognition mechanism of human beta-adrenergic receptor kinase 1 based on a 2-dimensional model structure. Drug Des Discov. 1996;14:145-155.
16. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol. 1982;161:269-288.
17. Shoichet BK, Bodian DL, Kuntz ID. Molecular docking using shape descriptors. J Comp Chem. 1992;13:380-397.
18. Meng EC, Shoichet BK, Kuntz ID. Automated docking with grid-based energy evaluation. J Comp Chem. 1992;13:505-524.
19. Gschwend DA, Kuntz ID. Orientational sampling and rigid-body minimization in molecular docking revisited: On-the-fly optimization and degeneracy removal. J Comput Aided Mol Des. 1996;10:123-132.
20. Kuntz ID. Structure-based strategies for drug design and discovery [see comments]. Science. 1992;257:1078-1082.
21. Sander C, Schneider R. Database of homology-derived protein structures and the structural meaning of sequence alignment. Proteins. 1991;9:56-68.
22. Rost B, Sander C. Improved prediction of protein secondary structure by use of sequence profiles and neural ne2rks. Proc Natl Acad Sci USA. 1993;90:7558-7562.
23. Rost B, Sander C. Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol. 1993;232:584-599.
24. Bernstein FC, Koetzle TF, Williams GJ, et al. The Protein Data Bank: A computer-based archival file for macromolecular structures. J Mol Biol. 1977;112:535-542.
25. Ferrin TE, Huang CC, Jarvis LE, Langridge R. The MIDAS Display System. J. Mol. Graph. 1988;6:13-27.
26. Sybyl v6.04a. Tripos Associates Inc., St. Louis, MO.
27. Connolly ML. Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983;221:709-713.
28. Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase [see comments]. Science. 1991;253:414-420.
29. MDL Information Systems Inc., San Leandro, CA.
30. Bemis GW, Kuntz ID. A fast and efficient method for 2D and 3D molecular shape description. J Comput Aided Mol Des. 1992;6:607-628.
31. Kameyama K, Haga K, Haga T, Kontani K, Katada T, Fukada Y. Activation by G protein beta gamma subunits of beta-adrenergic and muscarinic receptor kinase. J Biol Chem. 1993;268:7753-7758.
32. Wilden U, Kuhn H. Light-dependent phosphorylation of rhodopsin: Number of phosphorylation sites. Biochemistry. 1982;21:3014-3022.
33. Carrera AC, Alexandrov K, Roberts TM. The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP. Proc Natl Acad Sci USA. 1993;90:442-446.
34. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 1984;23:5036-5041.
35. Wang Z, Arden J, Sadee W. Basal phosphorylation of mu opioid receptor is agonist modulated and Cα2+-dependent. FEBS Lett. 1996;387:53-57.
36. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev. 1993;45:177-203.
37. Hanks SK. Eukaryotic protein kinases. Curr Opin Struct Biol. 1991;1:369-383.
38. Ring CS, Sun E, McKerrow JH, Lee GK, Rosenthal PJ, Kuntz ID, Cohen FE. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA. 1993;90:3583-3587.
39. Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 1989;258:156-158.
40. Mahoney CW, Azzi A, Huang KP. Effects of suramin, an antihuman immunodeficiency virus reverse transcriptase agent, on protein kinase C: Differential activation and inhibition of protein kinase C isozymes. J Biol Chem. 1990;265:5424-5428.
41. Baghdiguian S, Boudier JA, Boudier JL, Fantini J. Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. Cancer Lett. 1993;75:151-156.